BlueDot, a disease containment technology spinout set up by St Michael’s Hospital and Mars Innovation, has secured series A capital.

BlueDot, a Canada-based disease containment technology developer spun out in partnership with multi-institution commercialisation firm Mars Innovation, has attracted C$9.2m ($6.9m) in series A funding, BetaKit reported yesterday.
Insurance co-operative The Co-operators and Canadian government-owned venture arm BDC Capital co-led the round, investing through their respective funds Insurtech and Women in Technology Venture Fund.
Founded in 2008 as BioDiaspora, BlueDot develops products that enable healthcare, insurance and government customers to predict infectious disease risks, using artificial intelligence, big…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?